The-Changing-Map-For-Global-Biomanufacturing

This panel discussion from the Danaher Summit 2026, moderated by Cytiva China leader Alan Lee, brings together four senior leaders from Asia-Pacific biopharmaceutical companies to discuss the shifting global landscape of biomanufacturing. The panelists — Nan Zhang and Way Huang of Henlius, Jimmy Lee of WuXi XDC, and LC of Aogenics — share perspectives on China's rise as a biopharmaceutical innovation hub, ADC manufacturing complexity, and building resilient supply chains. China's license-out value reached $130 billion in 2025 and the landmark $15.2 billion BMS-Henlius deal exemplifies what panelists call a sustainable 'China moment.' Supply chain resilience and geopolitical diversification emerge as urgent strategic imperatives for all participants.

Key Takeaways

China's biomanufacturing license-out value reached $130 billion in 2025, and the $15.2 billion BMS-Henlius collaboration announced in May 2026 represents a structural shift toward China as a global pharmaceutical innovation partner, not just a manufacturing base.
Henlius was the first company approved for biosimilars in China, the first from China to earn EMA approval, and helped write China's CDE biosimilar guidelines; it now operates a dual-engine biosimilar and innovative drug pipeline with 10 products approved in 70+ countries.
WuXi XDC reduced ADC DNA-to-IND timelines from the 24-30 month industry average to 13-15 months through a fully integrated four-component platform at a single site — the only such facility globally — and is expanding to Singapore and the US.
ADC manufacturing faces a global drug-product bottleneck because every facility requires custom containment design for highly potent compounds; next-generation quad-conjugate and dual-linker-payload formats are adding further CMC and analytical complexity.
Taiwan's Aogenics draws an explicit parallel to TSMC's origin from a government-transferred semiconductor pilot unit; over 65% of Aogenics revenue comes from Japan and international clients, demonstrating Taiwan CDMO viability beyond its domestic market.
COVID-19 revealed extreme single-use consumable fragility (Taiwan CDMOs received one unit per order); ongoing geopolitical tensions have made magnesium chloride — shared with the DRAM semiconductor industry — nearly impossible to source from non-Chinese suppliers.
Biologic outsourcing stands at approximately 18% in 2025 and is forecast to reach 25% by 2030; approximately 118 biologics face patent expiry through 2035 but fewer than 10% have biosimilars in active development, signaling a large upcoming CDMO demand wave.